Introduction
The objectives of anti-asthma therapy are to abolish symptoms, prevent exacerbations and maintain normal lung function. A number of therapeutic approaches are available for the clinical management of this condition, including bronchodilators and anti-inflammatory agents. In general, a stepwise approach is recommended. Minimum therapy to maintain effective control should be used, with the level of therapy increased with increasing asthma severity.
Inhaled anti-inflammatory drugs are now re- 3 However, while older corticosteroids such as budesomide (BUD) and beclomethasone dipropionate (BDP) generally do not produce clinically significant systemic adverse effects at low doses, they may suppress the hypothalamic-pituitary:adrenal (HPA) axis function at higher doses. [4] [5] [6] There is therefore a clear need for new inhaled corticosteroids with a high topical potency combined with a reduced potential for systemic effects.
Fluticasone propionate (FP) is a topical corticosteroid which has been shown in vitro [9] [10] [11] [12] and over the whole 12- week treatment period (p= 0.003, Table 3 ). The (Table 4) . Similarly, the percentage of symptom-free nights improved from 28% at baseline to 80% between weeks 9 and 12 for FP, and 33% at baseline to 85% between weeks 9 and 12 for BUD (Table 4 ). There The range of minimum and maximum values for percentage of symptom-free nights at baseline was 0-88%. All other ranges were 0-100%. BUD budesonide; FP fluticasone propionate. The range of minimum and maximum values for percentage of days with no additional bronchodilator use at baseline was 0-88% in the fluticasone propionate (FP) group and 0-70% in the budesonide (BUD) group. The range for percentage of nights with no additional bronchodilator use at baseline was 0-88% in both groups. All other ranges were 0-100%.
bly related to study medication. The most common adverse events of any severity occurring during therapy are summarized in Table 6 . 
